SCANGOS GEORGE A Form 4

July 19, 2011

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

OMB APPROVAL

response...

if no longer subject to Section 16. Form 4 or Form 5

Check this box

obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and A SCANGOS	ddress of Repo GEORGE A	_	2. Issuer Name and T Symbol	Č	5. Relationship of Reporting Person(s) to Issuer			
			BIOGEN IDEC IN	C. [BIIB]	(Ch	eck all applicable	:)	
(Last)	(First)	(Middle)	3. Date of Earliest Trai	nsaction				
BIOGEN ID POST ROA		33 BOSTON	(Month/Day/Year) 07/14/2011		_X_ Officer (gi	ive title Other below) of Executive Office	er (specify	
	(Street)		4. If Amendment, Date	Original	6. Individual or	Joint/Group Filin	ıg(Check	
WESTON, I	MA 02493		Filed(Month/Day/Year)			y One Reporting Pe y More than One Re		
(City)	(State)	(Zip)	Table I - Non-De	rivative Securities Acq	uired, Disposed	of, or Beneficial	ly Owne	
1.Title of	2. Transaction	n Date 2A. Deer	ned 3.	4. Securities Acquired	5. Amount of	6. Ownership	7. Natur	

. •		Table	: 1 - MOII-D	erivative s	ecurn	ies Acq	jun eu, Disposeu o	n, or belieficial	ly Owned
1.Title of Security (Instr. 3)	2. Transaction Date 2A. Deemed (Month/Day/Year) Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)	4. Securities Acquired n(A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership
			Code V	Amount	(A) or (D)	Price	Following Reported Transaction(s) (Instr. 3 and 4)	(Instr. 4)	(Instr. 4)
Common Stock	07/14/2011		F	8,791	D	\$ 104	54,374	D	
Common Stock	07/15/2011		M	21,341	A	\$0	75,715	D	
Common Stock	07/15/2011		F	8,911	D	\$ 104	66,804	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control

Edgar Filing: SCANGOS GEORGE A - Form 4

number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	onDerivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	<u>(1)</u>	07/15/2011		M		21,341	(2)	07/15/2014	Common Stock	21,341

Reporting Owners

Reporting Owner Name / Address	Relationships							
reporting of their remains a remainder	Director	10% Owner	Officer	Other				
SCANGOS GEORGE A BIOGEN IDEC INC. 133 BOSTON POST ROAD WESTON, MA 02493	X		Chief Executive Officer					

Signatures

Aras Lapinskas, Attorney in Fact for George A.
Scangos
07/19/2011

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations, See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) There is no conversion or exercise price for this stock unit.
 - The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 150% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest on each of the first four anniversaries of the grant date.
- (2) The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average 60 calendar-day closing stock price ending on the vesting date divided by the average 60 calendar-day closing stock price on the grant date]).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2